AllenRP, WaltersAS, MontplaisirJ, et al.Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005; 165:1286–1292.
2.
FerréS, García-BorregueroD, AllenRP, EarleyCJ. New insights into the neurobiology of restless legs syndrome. Neuroscientist. 2019 [Epub ahead of print]; DOI:10.1177/1073858418791763.
3.
FerriR, RundoF, ZucconiM, et al.An evidence-based analysis of the association between periodic leg movements during sleep and arousals in restless legs syndrome. Sleep. 2015; 38:919–924.
4.
AllenRP, StillmanP, MyersAJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. Sleep Med. 2010; 11:31–37.
5.
TrenkwalderC, PaulusW. Restless legs syndrome: Pathophysiology, clinical presentation and management. Nat Rev Neurol. 2010; 6:337–346.
6.
SalminenAV, ManconiM, RimpiläV, et al.Disconnection between periodic leg movements and cortical arousals in spinal cord injury. J Clin Sleep Med. 2013; 9:1207–1209.
7.
LanzaG, CantoneM, LanuzzaB, et al.Distinctive patterns of cortical excitability to transcranial magnetic stimulation in obstructive sleep apnea syndrome, restless legs syndrome, insomnia, and sleep deprivation. Sleep Med Rev. 2015; 19:39–50.
8.
EarleyCJ, ConnorJ, Garcia-BorregueroD, et al.Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). Sleep Med. 2014; 15:1288–1301.
9.
ConnorJR, WangXS, AllenRP, et al.Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain. 2009; 132:2403–2412.
10.
García-BorregueroD, Cano-PumaregaI. New concepts in the management of restless legs syndrome. BMJ. 2017; 356:j104.
11.
García-BorregueroD, PatrickJ, DuBravaS, et al.Pregabalin versus pramipexole: Effects on sleep disturbance in restless legs syndrome. Sleep. 2014; 37:635–643.
YepesG, GuitartX, ReaW, et al.Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Ann Neurol. 2017; 82:951–960.
14.
QuirozC, OrrúM, ReaW, et al.Local control of extracellular dopamine levels in the medial nucleus accumbens by a glutamatergic projection from the infralimbic cortex. J Neurosci. 2016; 36:851–859.
15.
TrenkwalderC, AllenR, HöglB, et al.Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol. 2018; 17:994–1005.
16.
QuirozC, GulyaniS, RuiqianW, et al.Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome. Neuropharmacology. 2016; 111:160–168.
17.
FerréS, QuirozC, GuitartX, et al.Pivotal role of adenosine neurotransmission in restless legs syndrome. Front Neurosci. 2018; 11:722.
18.
Garcia-BorregueroD, GuitartX, Garcia MaloC, Cano-PumaregaI, GranizoJJ, FerréS. Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: Testing the adenosine hypothesis. Sleep Med. 2018; 45:94–97.
19.
FerréS, QuirozC, ReaW, GuitartX, García-BorregueroD. Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport. Adv Pharmacol. 2019 [Epub ahead of print]; DOI:10.1016/bs.apha.2018.12.005.
20.
LiX, EisenachJC. Adenosine reduces glutamate release in rat spinal synaptosomes. Anesthesiology. 2005; 103:1060–1065.
21.
Rivera-OliverM, MorenoE, Álvarez-BagnarolY, et al. Adenosine A(1)-dopamine D(1) receptor heteromers control the excitability of the spinal motoneuron. Mol Neurobiol. 2018 [Epub ahead of print]; DOI:10.1007/s12035-018-1120-y.
22.
FerréS. Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine. J Alzheimers Dis. 2010; 20(Suppl. 1):S35–S49.
23.
BrownRE, BasheerR, McKennaJT, StreckerRE, McCarleyRW. Control of sleep and wakefulness. Physiol Rev. 2012; 92:1087–1187.
24.
MishinaM, IshiiK, KimuraY, et al.Adenosine A(1) receptors measured with (11)C-MPDX PET in early Parkinson's disease. Synapse. 2017; 71:e21979.
25.
ElmenhorstEM, ElmenhorstD, BenderothS, KrollT, BauerA, AeschbachD. Cognitive impairments by alcohol and sleep deprivation indicate trait characteristics and a potential role for adenosine A(1) receptors. Proc Natl Acad Sci USA. 2018; 115:8009–8014.
